Stifel Resumes Ultragenyx Pharma (RARE) at Buy

March 1, 2021 4:06 PM EST
Get Alerts RARE Hot Sheet
Price: $108.72 -0.78%

Rating Summary:
    11 Buy, 10 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Stifel analyst Dae Gon Ha resumes coverage on Ultragenyx Pharma (NASDAQ: RARE) with a Buy rating and a price target of $179.00.

The analyst comments "Since its 2014 IPO, RARE has received three drug approvals (Mepsevii, Crysvita, and Dojolvi), completed an acquisition (DMTX), and pursued opportunistic business development (e.g., GeneTx, SLDB, MREO). Under the leadership of physician-trained CEO Dr. Emil Kakkis, RARE has been and continues to be relentless in developing meaningful therapies from a science-driven, patient-centric approach. Looking into 2021 and beyond, we believe RARE's prospects remain strong, with five clinical-stage assets poised to generate meaningful catalysts, while organic growth from commercial products are projected to generate $1B in revenues by 2025. We realize drug development — let alone receiving regulatory approvals — is notoriously difficult and recognize RARE hasn't been immune to adversities. Yet, the company's undeterred commitment to rare disease patients keeps us confident in its ability to innovate and execute as well as create value for shareholders."

For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.

Shares of Ultragenyx Pharma closed at $141.54 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Stifel, Definitive Agreement, IPO